Table 1.

Key information of the DAPA-MI trial [38]

DAPA-MI
Class & Cardiovascular (CV) outcomes	WR (95% CI)	p-value‡
Primary outcome
Composite of death, HHF, nonfatal MI, AF/flutter, T2D, NYHA class, body weight decrease ≥ 5%	1.34 (1.20 to 1.50)	< 0.001
Key secondary outcome
Composite of death, HHF, nonfatal MI, AF/flutter, T2D, NYHA class	1.20 (1.04 to 1.40)	0.015
Other secondary endpoints	HR (95% CI)
Composite of CV death/HHF	0.95 (0.64 to 1.40)
CV death/HHF/MI	0.95 (0.70 to 1.29)
MACE (MI, stroke, or CV death)	0.94 (0.67 to 1.31)
All-cause death	1.22 (0.77 to 1.92)
CV death	1.15 (0.66 to 2.01)
MI	1.11 (0.72 to 1.71)
Stroke	0.61 (0.28 to 1.34)
New diagnosis of T2D	0.53 (0.36 to 0.77)
New diagnosis of AF/flutter	0.88 (0.45 to 1.73)
All-cause hospitalization	1.12 (0.97 to 1.29)
Adjudicated HHF	0.83 (0.50 to 1.39)

‡ Only significant p-values are presented

AF, atrial fibrillation; CI, confidence interval; CV, cardiovascular; HF, heart failure; HHF, hospitalization for HF; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; NYHA, New York Heart Association; T2D, type 2 diabetes; WR, win ratio